High-frequency irreversible electroporation synergizes with PD-1/PD-L1 inhibitor BMS-1 and TLR7/8 agonist R848 to potentiate liver cancer antitumor immunity

Figure 4 High-frequency irreversible electroporation combined with BMS-1 and R848 impairs tumor cell viability and suppresses proliferation in hepatoma 22 subcutaneous tumors. A: Schematic of the hepatoma 22 subcutaneous tumor-bearing mouse model and treatment regimen; B: Weight of excised subcutaneous tumors from the right flank at 1 week post-treatment; C: Hematoxylin-eosin staining of subcutaneous tumor sections across treatment groups (n = 8); D: Quantitative analysis of Ki67-positive rate (%) in right-sided subcutaneous tumors 1 week post-treatment (n = 8); E: Representative images of Ki67 immunohistochemical staining in right-flank subcutaneous tumors 1 week post-treatment. ^cP < 0.001, and ^dP < 0.0001. i.p.: Intraperitoneal; i.t.: Intratumoral; H-FIRE: High-frequency irreversible electroporation; H22: Hepatoma 22.